Gefitinib (GEF) acts reversibly on wild-type and certain mutant EGFRs and inhibits the autologous phosphorylation of EGFR tyrosine, thereby further inhibiting downstream signaling and promoting tumor metastasis. The gene discussed is EGFR; the disease is neoplasm.